Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
Currently approved human epidermal growth factor receptor 2 (HER2)-targeted antibody therapies are largely derived from trastuzumab, including trastuzumab-chemotherapy combinations, fixed-dose trastuzumab-pertuzumab combinations, and trastuzumab antibody-drug conjugates. To expand the options, bispe...
I tiakina i:
Ngā kaituhi matua: | , , , , , , , , , , , , , , , , |
---|---|
Hōputu: | Pukapuka |
I whakaputaina: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Ngā marau: | |
Urunga tuihono: | Connect to this object online. |
Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Ipurangi
Connect to this object online.3rd Floor Main Library
Tau karanga: |
A1234.567 |
---|---|
Tārua 1 | Wātea |